Neurogt, Inc.
Publicly observedChapel Hill, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Chapel Hill | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Neurogt, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | NQHRNCAD21P3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant16 Sept 2025Publicly observed
NIH SBIR/STTR award: Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I
USD 1,484,525.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant16 Sept 2025Publicly observed
NIH SBIR/STTR award: Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I
USD 1,499,504.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant8 Jul 2025Publicly observed
NIH SBIR/STTR award: Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC
USD 342,740.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant8 Jul 2025Publicly observed
NIH SBIR/STTR award: Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC
USD 349,909.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2024Publicly observed
NIH SBIR/STTR award: Development of gene therapy product for treating MPS IIIB
USD 1,341,983.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2024Publicly observed
NIH SBIR/STTR award: Development of gene therapy product for treating MPS IIIB
USD 1,305,826.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2023Publicly observed
NIH SBIR/STTR award: Protein depleting pre-existing antibodies for viral gene therapy
USD 969,817.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.